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Abstract
The goal of this study was to identify the baseline host and viral factors of response to 
antiviral therapy in patients with chronic hepatitis C. Compared with interferon/ribavirin 
therapy, new current direct-acting antiviral (DAA) combination regimens significantly 
increased rate of sustained virologic response (SVR) and shorter treatment durations, but 
is still limited by viral resistance, adverse effects, and high cost especially in  developing 
countries. Human genetic factors and heterogeneity within the HCV genome may be 
associated with virologic treatment failure before and after antiviral therapy. Further, 
HCV infection may contribute to the development of HCV-related liver disease and 
hepatocarcinogenesis, through modulating genetic and epigenetic state of certain genes 
implicated in control of critical cellular pathways. Previous results confirm the impor-
tance of host and viral factors and virus-induced genetic and epigenetic changes in pre-
dicting outcome and treatment response.
Keywords: hepatitis C virus, response to therapy, IFN-based antiviral therapies, direct-
acting antiviral (DAA) agents, genetic variability, liver fibrosis, hepatocarcinogenesis, 
epigenetic changes
1. Introduction
Chronic hepatitis C virus (HCV) infection with the estimated worldwide prevalence of 1.1% 
is a global health problem, affecting 170 million people worldwide [1, 2]. About 15–45% of 
infected persons spontaneously clear the virus without any treatment, but remaining 60–80% 
will develop chronic HCV infection leading to fibrosis, cirrhosis and/or hepatocellular 
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carcinoma (HCC) [1, 3]. Previous results suggest that, worldwide, there were 1.75 million new 
HCV infections and annually an estimated 700,000 persons with chronic HCV die untreated 
[1]. Until 2014, the standard of care to treat HCV infection was pegylated interferon and riba-
virin (PEG-IFN and RBV). However, first generation of (DAAs) NSA3/4A protease inhibitors 
(PI) were boceprevir and telaprevir, administrated with PEG-IFN and RBV [1]. These protease 
inhibitors were limited by viral resistance, adverse effect and long treatment duration and 
high cost especially in development countries [4]. The standard care of therapy is changing 
rapidly and new (DAAs) therapy such as sofosbuvir, daclatasvir, and the sofosbuvir/ledipas-
vir combination are part of the preferred regimens in the WHO guidelines with achieve cure 
rates above 95%. In comparison with older therapies, new therapy is more effective, safer, and 
better-tolerated with shorter treatment (usually 12 weeks), but high prices of the medicines 
limit the expansion of HCV in many countries [1]. However, challenges remain in optimiz-
ing current drug regimens, limiting the problem of resistance mutations and promote indi-
vidual therapy [5–7]. Treatment predictors are important factors for management of therapy 
in patients with chronic hepatitis C infection.
1.1. Host and virus-related factors associated with response to therapy
Previous studies indicated that baseline host and virus related factors such genotype, viral 
load, age, gender, stage of liver fibrosis, and IL28B (interleukin-28B) polymorphisms were asso-
ciated with therapy outcome [8–16]. Among viral factors, HCV genotype and baseline level of 
HCV-RNA are significant determinants of treatment outcome. Sustained virologic response 
(SVR) was defined as undetectable levels of HCV RNA, 24 weeks after cessation of treatment. 
Rapid virologic response (RVR) was defined as undetectable levels of HCV RNA at 4 weeks. 
Early virologic response (EVR) was defined as undetectable levels of HCV-RNA at week 12 
(complete EVR) or ≥2 log reduction in HCV viral load from baseline (partial EVR), while non-
response NR was defined as detection of serum HCV RNA 6 months after cessation of treat-
ment. Thus, RVR is a strong predictor of SVR, but absence of an EVR is significant predictor 
for non-response (NR) to antiviral treatment. Moreover, viral kinetics during therapy provides 
information on how to individualize treatment [16, 17]. It is known that stages of liver fibro-
sis may be associated with response rates to PEG-IFN/RBV therapy. Further, patients with 
advanced liver fibrosis (METAVIR score F3-F4) were more frequently in non-responders (NR) 
than in patients with minimal or mild fibrosis (F0-F2), especially in patients with genotype 1 [8, 
12, 18]. According to the previous results, infection with genotypes 2 or 3, younger ages, lower 
baseline viral load, and absence of advanced fibrosis were all strong predictors of SVR. Since 
2011, therapeutic regimens for HCV genotype 1 patients were modified. Combination of 
NS3/4a protease inhibitors and pegylated interferon and ribavirin improved the SVR rates [19]. 
However, boceprevir- and telaprevir-based regimens are associated with side effect and lower 
efficacy than the newer DAA therapies. Also, this therapy is effective only in patients with gen-
otype 1 [1, 20]. With respect to host and viral factors and first generation DAAs, viral kinetics is 
the most important predictive factor of SVR. The IL28B was associated with greater chances to 
shorten therapy but there is no correlation with SVR [8]. Second-generation DAAs have higher 
rates of SVR, are safer and can be used in combinations that obviate the need for interferon and 
ribavirin [1]. However, failure to new DAAs combinations is in association with patients with 
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poor response, genotypes 1a or 3, advanced liver cirrhosis, elevated level of viral load and the 
presence of human immunodeficiency virus (HIV) coinfection [21]. In contrast, some authors 
suggest that therapy outcomes are not significantly influenced by IL28B polymorphisms, HCV 
genotype, high baseline viral load, or prior interferon failure [22]. In the era of DAAs, surveil-
lance of HCC after eradication of HCV by antivirus therapy is particularly important. Current 
new therapies with DAAs are associated with high rates of SVR, generally exceeding 90% even 
among patients with cirrhosis or prior treatment failure. Therefore, understanding of various 
host and viral factors associated with disease progression and development of HCC in chronic 
hepatitis C infection is important for implementing personalized treatment. One of the most 
interesting current questions concerns the impact of DAAs on HCC incidence [23].
1.2. HCV-host interactions and host genetic alterations
In the specific environment of every host, the outcomes of the HCV infection will be different. 
There are many factors which influence the therapy outcome and progression of liver disease. 
These factors include baseline clinical and pathohistological parameters. Also, host genetic 
landscape has effects on therapy outcomes and development of liver disease phenotypes. 
Genome-wide association studies (GWAS) have been created to track genetic polymorphisms 
in the human genome which associate with, virus clearance, therapy outcomes, and different 
stages of liver disease. Thus, this kind of the genome screening could be a useful tool in the 
diagnostics and the therapy of hepatitis C, and could lead to a personalized therapy.
1.2.1. Role of interferons (IFN) in HCV infection
HCV infection induces production of interferons λ (IFN-λ). IFN-λs bind to IFNL receptors (IFNLR) 
activating JAK-STAT signaling pathway which induces expression of ISGs (interferon-
stimulated genes). The IFNLR is a heterodimer, consisting of two subunits, IL10R2 and 
IL28RA. There are four IFN-λs described so far: IFNL 1–4. The gene loci for these proteins are 
located on the chromosome 19. Study of GWAS has revealed polymorphisms in IFNL gene 
loci, which are in association with HCV clearance, either spontaneous or therapy-induced. 
Previously it was shown that single nucleotide polymorphisms (SNPs) near IL28B (rs12979869 
and rs8099917) were strongly associated with response to PEG-IFN/RBV therapy in patients 
with genotype 1 and with spontaneous virus clearance [24–27]. In the neighborhood of ILR3, a 
novel dinucleotide polymorphism, ss469415590 (TT/ΔG), has recently been discovered which 
is in high linkage disequilibrium with rs12979869 and participate in formation of a novel gene 
IFNL4. The IFNL4 gene creates IFNL4 protein, but TT variant of ss469415590 does not form 
the protein [28]. The TT variant has been shown to be beneficial to its carriers because it influ-
ences the spontaneous and therapy-induced virus clearance [26]. Among people of African 
ancestry, the polymorphism ss469415590 is in stronger association with virus clearance than 
the rs12979869 [28]. There are two variants of IFNL4 protein with impact on antiviral activ-
ity, which differ in only one amino acid at the place 70. The carriers of the variant with serine 
(P70S) have better therapy response and higher spontaneous virus clearance rate compared 
to carriers of the variant with proline. However, the expression of ISGs in the variant P70S 
is decreased, which is in discrepancy with its better antiviral activity. The researchers have 
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speculated this is probably due to decreased adaptive immunity as the consequence of high 
expression of ISGs in carriers of IFNL4-P70 variant [28]. The genes of human leukocyte antigen 
(HLA) family located on the chromosome 6 are associated with clearance of HCV infection. 
Some authors found that this connection is inconsistent, because of different systems of HLA 
typing, clinical phenotypes, and ethnic backgrounds. The only polymorphisms of HLA genes 
which are confirmed so far to have an association with virus clearance are HLA-DQB1*03 
and HLA-DRB1*11 [29–32]. The receptors of natural killer (NK) cells Killer-cell immunoglob-
ulin-like receptors (KIR) and their corresponding ligands, HLA class 1 proteins, also have 
a role in the immune response. Studies of the association of the polymorphisms of KIR and 
HLA-C and virus clearance have given controversial results. In some studies, the carriers of a 
KIR2DS3 (killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 
3) and homozygosity for HLA-C1 were associated with spontaneous virus clearance [33, 34]. 
Polymorphisms of some other genes coding for the proteins which have a role in the immune 
response have also been shown to correlate with spontaneous/therapy-induced virus clear-
ance. One of these genes is the gene for osteopontin which initiates T helper cells type 1 
response, and has been shown to associate with the sustained viral response after the IFN 
therapy [35, 36]. Today, the role of the host genetic variability has been reduced due to high 
efficacy of new era interferon-free antiviral therapy. However, the high cost of this therapy 
limits its availability to the developed parts of the world.
1.2.2. The influence of host genetic alterations on the progression of liver fibrosis in chronic 
HCV infection
On the other hand, the host genetic variability has a significant role in the formation of dif-
ferent liver phenotypes. The phenotypes, such as fibrosis, steatosis, cirrhosis, or hepatocel-
lular carcinoma (HCC) are the consequence of virus infection and disease progression. The 
polymorphisms of the immune response genes have effect on disease progression or inhibi-
tion. For example, the patients with chronic hepatitis C, which carry rs12979860CC variant, 
have higher fibrosis progression rate. This effect is even more pronounced in the younger 
females and in the carriers of the HCV type 3 [37]. The polymorphisms of apoptosis-related 
genes MERTK (MER proto-oncogene, tyrosine kinase), TULP1 (tubby like protein 1) and RNF 
(ring finger proteins) gene family have association with the progression of the HCV-related 
fibrosis [38] and the genes of the major histocompatibility complex (MHC) with cirrhosis [39] 
and HCC [40]. However, these results need confirmation in the further research. Although 
having some potential, GWAS studies have many flaws. One of them is the impossibility 
of the screening of more extensive genetic changes, e.g., copy number variation (CNV) and 
epigenetic events, which also take part in the disease progression and the therapy response. 
Methodological failure is that these studies use conservative significance thresholds to elimi-
nate false positive signals and many significant polymorphisms of low frequency could be 
unregistered, as reviewed in [41]. All discovered polymorphisms so far are currently not 
applicable to the clinical classification of the liver disease, because of their low predictive 
value. One of the possible solutions is the formation of the polygenic scores. For example, 
there is an earlier study which resulted in the formation of cirrhosis risk scores (CRS) based on 
the gene signature of seven genes [42]. In another study, a prediction model for liver fibrosis 
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was based on gene polymorphisms. This model includes polymorphisms of IFNL and clinical 
risk factors, which taken together give a risk for liver fibrosis [43]. Based on the fibrosis/cirrho-
sis risk score, therapy decisions can be made. Chronic inflammation and cirrhosis of hepatic 
cells lead to HCC. Hepatocellular carcinoma is the one of the deadliest type of cancer in the 
world. It represents a heterogeneous disease consisting of many tumor subpopulations with 
different frequencies of mutated genes. There are several genes which are affected, during the 
HCC progression, either by genetic or epigenetic alterations. In recent studies, the alterations 
of the TERT (telomerase reverse transcriptase), CTNNB1 (catenin beta 1), TP53 (tumor protein 
p53), and AXIN1 (axin 1) genes are shown to correlate with tumor progression [44, 45]. TERT 
promoter mutations have been present in 64% of HCV-related HCC [44]. TERT is a subunit 
of the telomerase enzyme, whose mutations lead to telomere shortening and uncapping of 
chromosomes, which then leads to chromosome fusion and general chromosomal instabil-
ity. TERT mutations and silencing of CDKN2A (cyclin dependent kinase inhibitor 2A) gene 
by promoter hypermethylation are the events that coincided [46]. It seems that TERT muta-
tion is an early event in the cancerogenesis [45]. Frequent CTNNB1 mutations have also been 
observed in HCV-related HCC [46]. There were attempts to classify HCC based on genetic 
signatures. The genetic signature represents one gene or a collection of genes, with charac-
teristic expression profile, which is confirmed to be specific for the diagnosis, prognosis, and 
treatment response prediction [47]. Genetic signatures could be the means of classifying HCC 
in the groups which would facilitate diagnosis and therapy decisions. In the first attempt to 
make a molecular model for a diagnosis of an early HCC in the HCV patients, the best accu-
racy was achieved using the signature of three genes LYVE1 (lymphatic vessel endothelial 
hyaluronan receptor 1), GPC3 (glypican 3), and BIRC5 (baculoviral IAP repeat containing 
5). The TERT gene and E-cadherin were also shown to be informative in that model [48]. One 
European study revealed molecular signatures of 243 HCCs, based on fibrosis and cirrhosis 
score, and various risk factors, among which HCV was present in 26% of the cases. However, 
this study did not find any associations of these molecular signatures with HCV infection [45]. 
Cancer Genome Atlas Research found 26 frequently mutated genes in HCC. They identified 
ALB (albumin), APOB (apolipoprotein B), LZTR1 (leucine zipper like transcription regulator 
1), EEF1A1 (eukaryotic translation elongation factor 1 alpha 1), SMARCA4 (SWI/SNF related, 
matrix associated, actin dependent regulator of chromatin, subfamily a, member 4), AZIN1 
(antizyme inhibitor 1), RP1L1 (retinitis pigmentosa 1 like 1), GPATCH4 (G-patch domain con-
taining 4), CREB3L3 (cAMP responsive element binding protein 3 like 3), AHCTF1 (AT-hook 
containing transcription factor 1) and HIST1H1c (histone cluster 1 H1 family member c) gene 
mutations. Additionally, this study used methylation profiles, based on which the HCC 
were divided into four methylation clusters. The fourth cluster was characterized by high 
frequency of CTNNB1 and TERT mutations, CDKN2A promoter hypermethylation and pres-
ence of HCV infection [46]. Besides smaller genetic changes, the changes which encompass 
bigger regions of DNA such as deletions, insertions, copy number variations, loss of hetero-
zygosity also have a role in the HCC progression. All of these changes alongside hyper and 
hypomethylation lead to general chromosomal instability, which is prerequisite for tumor 
progression. There are examples of the direct influence of HCV on host genomic instability. 
HCV protein NS5A interacts with host gene ASPM (abnormal spindle microtubule assembly), 
which regulates mitotic spindle formation, causing interruption of the cell cycle,  eventually 
Hepatitis C: Host and Viral Factors Associated with Response to Therapy and Progression of Liver…
http://dx.doi.org/10.5772/intechopen.76417
143
leading to chromosomal instability and HCC [49]. HCV Core protein induces polyploidy 
by decreasing of retinoblastoma-associated protein expression, thereby influencing mitotic 
cycle checkpoint, which also leads to chromosomal instability [50]. In addition, interaction of 
NS3/4A with serine protein kinase, which has a role in the cell cycle, leads to disabling cell 
repair system [51]. The polymorphisms in the host genome have effect on therapy response, 
virus clearance, and differentiation of HCV-induced liver phenotypes. The genetic signatures 
in the host genomes could be the means of therapy decisions making, and a way to personal-
ize therapy. However, some other factors, such as epigenetic events and alterations of larger 
DNA regions, should also be taken into an account.
1.3. Impact of hepatitis C virus heterogeneity on therapy outcomes
The persistence of hepatitis C virus (HCV) infection and its poor susceptibility to treatment 
have been attributed, at least in part, to the high rate of genetic variability exhibited by the 
virus.
The persistence of HCV infection and its poor susceptibility to treatment is the consequence 
of high rate of virus genetic variability. Variability of virus is due to the low fidelity of viral 
RNA-dependent RNA-polymerase, which lacks proof-reading capacity, thus allowing the 
generation of quasispecies. Genetic variability is segregated within particular segments of 
the HCV genome, resulting in a number of highly variable regions [52]. These quasispecies 
play an important role in the escape from selective pressures by immune responses and 
antiviral therapies. A decrease or no change in the number of nucleotides substitutions in the 
protein kinase (PKR) binding domain (PKRBD) and the interferon-sensitivity-determining 
region (ISDR) were associated with failed to respond to PEG-IFN/RBV treatment [53]. It was 
reported that the presence of >4 mutations in the PKRBD region of NS5A protein was cor-
related with SVR to peg-IFN/RBV therapy [54]. Moreover, PKRBD sequences might be used 
as a prognostic guide for treating HCV-1-infected patients [54, 55]. Absence of substitutions 
at positions 70 and 91 in Core protein is a significant predictor for the success of IFN-based 
therapy [54]. On the other side, amino acid substitutions in the Core protein play an impor-
tant role in early dynamics of viral replication during IFN-based therapy in chronic HCV 
infection and more frequent occurrence HCC. With respect to new DAAs therapy, efficacy 
of NS5A inhibitors can be blocked by presence of NS5A resistance-associated substitutions 
(RASs), but choice of DAA regimen and duration of therapy depends on multiple viral and 
host factors.
2. Epigenetic changes in HCV-induced liver diseases
Persistent infection with HCV is associated with the development of chronic liver diseases: fibro-
sis, cirrhosis and ultimately, HCC [56, 57]. Prevention of chronic hepatitis C and its complica-
tions is based on antiviral therapy and early detection of reliable molecular markers in persons 
under the risk [57, 58]. However, current antiviral therapies are not effective in many patients 
with chronic hepatitis C, so there is a need for a greater understanding of the factors leading 
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to progression to HCC in order to design novel approaches to prevention of HCV-associated 
complications [59]. Here, we discuss the current knowledge about the inter-relationship 
between HCV and pathophysiology of HCV-associated chronic liver diseases, with particular 
focus on the virus-induced host epigenetic changes leading to hepatocarcinogenesis.
2.1. Hepatocellular carcinoma
According to epidemiological evaluation, HCC is the fifth most common cancer and the second 
most common cause for cancer death in the world [60]. Although the prognosis of patients with 
HCC has marginally improved over the last few decades, the five-year survival rate remains 
poor as a result of late diagnosis. Consequently, the majority of patients with advanced HCC do 
not survive for longer than 6 months from the time of diagnosis [61]. It has been shown that in 
chronically infected patients, the risk of developing HCC is strictly correlated to fibrosis stage, 
and the incidence of HCC is more frequent in patients with liver cirrhosis than in those with mild 
fibrosis [62]. SVR to IFN-based therapies decreases HCC incidence in a large number of HCV 
patients, indicating the importance of eradicating the virus to prevent carcinogenesis [63, 64]. 
However, despite a successful virus clearance, the risk of HCC still exists in individuals with 
severe fibrosis and continuous HCC monitoring is recommended [65]. So, it is of great impor-
tance to determine molecular markers of progressive fibrosis, that could indicate the chronically 
HCV infected persons under the risk of developing HCC [66, 67]. HCV-induced hepatocar-
cinogenesis is a multifactorial process which results from a complex interaction among host, 
environmental, and viral factors [67]. It is considered that at least three host cellular pathways 
are affected in this process: cell cycle, proliferation, and apoptosis [68]. As HCV is an RNA virus 
with limited integration of its genetic material into the host’s genome, it was first assumed that 
its ability to transform hepatocytes is linked to indirect mechanisms. Chronic inflammation 
induced by viral infection results in a permanent degenerative and regenerative processes and 
occurrence of progressive fibrosis and cirrhosis [69–71]. In addition, chronic inflammation leads 
to increased levels of reactive oxygen species (ROS), which damage hepatocytes and can lead to 
accumulation of genetic and epigenetic alterations in hepatic cells [67, 72]. All these events can 
promote neoplastic transformation of hepatocytes and the progression of malignant clones [73]. 
Later studies have shown that HCV is directly involved in hepatocarcinogenesis, through direct 
action of viral proteins on host tumor suppressors and proto-oncogenes [74, 75]. Several viral 
proteins have been shown in vitro to possess functions that could favor hepatocarcinogenesis, 
through inducing genetic and epigenetic alterations. In particular, the Core protein, NS3, NS4B 
and NS5A can transform various cell lines, either alone or in cooperation with oncogenes [76–
80]. These proteins interact with a number of host factors and signaling pathways leading to the 
progression from chronic hepatitis C to liver cirrhosis and HCC [68].
2.1.1. Epigenetic changes in HCV-induced HCC
Many lines of evidence suggest that aberrant epigenetic changes associated with viral infec-
tion may trigger events that promote the neoplastic transformation of hepatocytes [59, 73]. 
Epigenetics is defined as heritable state of gene expression without altering DNA sequen-
ces. Epigenetic mechanisms include genomic DNA methylation, chemical modifications 
Hepatitis C: Host and Viral Factors Associated with Response to Therapy and Progression of Liver…
http://dx.doi.org/10.5772/intechopen.76417
145
of histone tails, and non-coding miRNA regulation [81]. Epigenetic changes play a critical 
role in control of cellular processes through switching genes on and off, thus leading to dif-
ferential expression of proteins [82]. HCV infection has been shown to induce or correlate 
with some epigenetic changes that may contribute to HCV-related liver diseases, including 
hepatocarcinogenesis [68]. It has been proven that certain HCV-encoded proteins induce 
promoter methylation of multiple genes, thereby affecting their expression [83, 84].
2.1.2. Host genes promoter methylation induced by HCV
DNA methylation represents the addition of methyl group (CH
3
) to a fifth carbon of cytosine 
residues within a CG dinucleotide, frequently referred to as cytosine-guanine dinucleotide 
(CpG). DNA methylation is an essential component of epigenetic machinery that regulates 
transcriptional state of many genes. Methylated promoters often lack transcriptional activ-
ity, which could result in gene inactivation. As a transcriptional regulator, DNA methyla-
tion has a considerable impact on the development of many cancers, including HCC [81, 85]. 
Aberrant promoter hypermethylation of tumor suppressor genes involved in the cell prolif-
eration, apoptosis, cell adhesion, DNA repair, and detoxification is frequently detected in 
HCC, resulting in loss of the corresponding gene function [86, 87]. It is believed that changes 
in DNA methylation patterns are early events in hepatocarcinogenesis and they can even 
occur at the early stages of HCV induced liver fibrosis [88]. This is supported by the results of 
the study conducted by Zekri et al., in which they demonstrated that methylation of certain 
host genes increase with liver disease progression, from fibrosis to HCC [89]. Moreover, the 
same group of authors has been shown that methylation of certain tumor suppressor genes 
affect the response to the antiviral therapy [90]. Considering this, a better understanding of 
methylation changes and how they correlate with disease progression will help in finding 
novel biomarkers for early detection of HCC and its prevention.
2.1.3. HCV-encoded proteins inducing host genes methylation
It has been demonstrated that HCV Core protein up-regulates levels of DNA methyltransfer-
ase (DNMT) 1 and 3b and induces promoter hypermethylation of tumor suppressor genes 
like p16 (CDKN2A) and E-cadherin [91, 92]. Consequent inhibition of p16 expression results in 
inactivation of pRb (retinoblastoma protein) and subsequent activation of E2F transcription 
factor 1 (E2F1), which lead to growth stimulation of hepatocytes. Inactivation of p16 tumor 
suppressor gene, that regulates cell cycle, appears to play an important role in the pathogenesis 
of HCC. It has been demonstrated that reactivation of p16 by transferring the p16 gene can 
inhibit the proliferation and reduce the invasive ability of HCC cells [93]. Down-regulation 
of E-cadherin by Core-induced hypermethylation leads to epithelial-mesenchymal transition, 
cell detachment from the surrounding matrix, and migration outside of the primary tumor 
site, which is known to be a critical event during the late stage of carcinogenesis [94]. Besides 
these, methylation of some other tumor suppressor genes, like suppressor of SOCS-1 (cytokine 
signaling 1), GSTP1 (glutathione S-transferase pi 1), APC (adenomatous polyposis coli), and 
RASSF1A (Ras association domain family member 1), has been detected in HCV-associated 
HCC compared normal liver [95, 96]. Abnormal promoter methylation of most of these genes 
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was detected in the plasma/serum DNA as well as in the tissue DNA of HCC patients, which 
gives opportunity for designing noninvasive blood tests for detection of methylation markers 
and to distinguish HCV patients who will eventually progress to advanced stages of fibro-
sis [97]. Zhang et al. reported that the analysis of methylation status of RASSF1A, p16, and 
p15 (cyclin-dependent kinase inhibitor 2B, CDKN2B) in serum DNA of infected people could 
be a valuable biomarker for early detection of HCC in the populations at high risk, includ-
ing chronic HCV infection [98]. Iyer et al. recorded high frequencies of p15, p16, APC, FHIT 
(fragile histidine triad), and E-cadherin promoter methylation in the plasma and liver tissue 
of HCV-associated HCC patients, with high concordance for all examined genes [99]. Zekri 
et al. have shown that methylation of MGMT (O-6-methylguanine-DNA methyltransferase) 
gene can be used as a predictor of response to the antiviral therapy, while RASSF1A methyla-
tion status could be a marker of fibrosis severity [90]. As authors reported, promoter methyla-
tion of MGMT gene appeared at higher frequencies in the NR than in the responders, which 
was explained by the fact that MGMT has an important role in protecting cells against DNA 
damage, via triggering DNA repair mechanisms [100]. On the other hand, the same group of 
authors has shown that RASSF1A methylation was significantly higher in HCV patients with 
mild fibrosis, which support the role of an intact RASSF1A gene in inducing the fibrogenesis 
in chronic HCV patients [90]. Another study by Hayashi et al. reported that HCC patients with 
SVR have different molecular alterations compared to NR with continuous HCV infection [101]. 
This group of authors observed lower frequencies of p16, RB1 (RB transcriptional corepressor 
1) and PTEN (phosphatase and tensin homolog) genes promoter hypermethylation in patients 
with SVR, while methylation of p15 and p14 (ARF tumor suppressor) genes was not detected 
in this group of patients, compared to those with the present HCV infection. Interestingly, p16 
methylation was detected with the highest frequency in the both groups, suggesting important 
role of p16 gene in the development of SVR-HCC. Authors speculated that p16 in hepatic stem 
cells might be methylated in the continuous presence of HCV. These cells with methylated p16 
gene might survive and grow after eradication of HCV by IFN therapy. In addition, despite an 
improved understanding of mechanisms leading to HCV-induced HCC and development of 
highly potent antiviral therapy, HCV-related HCC remains a global health problem. The devel-
opment of valuable molecular biomarkers will be of a great importance to distinguish a group 
of HCV infected people with a high risk for hepatocarcinogenesis. Based on the studies con-
ducted so far, genomic DNA methylation could function as a non-invasive, sensitive, and spe-
cific biomarker for prediction the response to the antiviral therapy and early detection of HCC.
2.2. MicroRNA biogenesis and function
MicroRNA (miRNA) are non-coding genetic elements participating in the regulation of gene 
expression by RNA interference in plants and animals, while in human cells, are associated 
with viral infection, as well. According to The Encyclopedia of DNA Elements (ENCODE), 
approximately 75% of the human genome transcribes into a various types of RNA molecules, 
coding and non-coding [102, 103]. Among non-coding RNA (ncRNA), miRNAs emerged as 
biologically, physiologically, and clinically significant, considering the fact that they silence 
translation of partially complementary target messenger (mRNA) molecules. MicroRNAs 
participate in the regulation of gene expression by RNA interference. In the last 15 years, 
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miRNAs were linked with various types of diseases and disorders, and majority of investi-
gations were based on the changes in their expression levels. MicroRNAs are encoded by a 
miRNA gene, which transcribes into an immature-primary microRNA (pri-miRNA) mole-
cule, a double stranded, hairpin-like genetic structure. Then, two enzymes-RNase endonucle-
ase III Drosha, and DGCR8 (molecular anchor part of a microprocessor complex), transform 
pri-miRNA into a 70 nucleotides (nt) long precursor microRNA (pre-miRNA) in the nucleus 
[104]. The process of miRNA maturation occurs in the cytoplasm, where Dicer or Argonaute 
(Ago), and other protein-partners, cooperators cleave pri-miRNA into a 22 nt long miRNA, 
ready to be recognized by RNA-induced silencing complex-RISC [105, 106]. The recognition 
and binding of miRNA “seed” sequence to 3′ untranslated region (3’UTR) of target mRNA 
incompletely complementary with “seed” region at miRNA molecule results in either trans-
lational repression, or mRNA degradation. Translational repression and degradation result 
in the decrease of protein levels, thus changing genetic, biological, and physiological pro-
cesses, activity of various signaling pathways. So, main characteristic of miRNAs is to regu-
late amounts of synthesized proteins [107]. miRNAs are present in every human cell, and 
in body fluids (as circulating), such as serum, plasma, urine, saliva, and even gingival liq-
uid. MicroRNA circulates through the body via body fluids as free-circulating miRNAs, and 
packed into the exosomes and vesicles, as exosomal miRNAs. Extracellular, exosomal circu-
lating miRNAs may carry over the information about disease progression, infection status, 
and other clinic pathological parameters of HCV infection and HCC formation and progres-
sion, but it is still not completely clear. Liver-specific miRNAs such as miR-122 and miR-192, 
may be released from damaged liver cells, providing the information about liver. Exosomal 
and circulating miRNAs, as well as miRNAs extracted from tissue may be involved in inter-
cellular communication. Besides the fact that nearly 300 miRNAs are expressed in normal, 
healthy liver, miR-122 represents the major fraction of liver-specific miRNAS, together with 
miR-192, miR-199a/b-3p, miR-101/99a, and members of oncogenic let-7 family [108].
2.2.1. MicroRNA in HCV infection and HCC
MicroRNAs are described as onco miRNAs, some of them as tumor suppressive, and several 
of them even have dual role in cancer pathogenesis and presumably in other physiological 
processes and pathological condition [109]. During the HCV infection, onco miRNAs such 
as miR-21/155/221 activate and might cause formation and facilitate progression of HCC. On 
the other hand, the decrease of some tumor suppressive miRNAs during the HCV infection 
might also cause hepatocarcinogenesis, such as miR-198 [110]. Firstly, some miRNAs directly 
interact with the genome of HCV. Secondly, several miRNAs are potential biomarkers of the 
presence or progression of the HCV infection. Thirdly, several miRNAs are indicators of HCC 
formation and/or progression. Fourthly, there are miRNAs associated with HCC genotype and 
clinicopathological characteristics of infected patients and histopathological characteristics of 
tumors, while some miRNAs such as miR-134/320c/483-5p may be used as early biomarkers 
for HCV infection in the future. Finally, some miRNAs, such as miR-122 represent potentially 
great targets for future therapeutics in the aspects of treatment of HCV-associated liver dis-
eases and HCC. Large numbers of different studies have recently been focused on miRNAs in 
a different points related to different points of HCV infection, i.e., replication of the virus, viral 
Hepatitis C - From Infection to Cure148
genotype, response to HCV therapy, lipid status, liver function indicators, stage of liver fibrosis, 
HCC grading, and response to chemotherapy. Changes in the expression levels of miRNA sev-
eral micro RNAs such as miR-21/122/134/141/155/192/199/221/320c/373/483-5p/491/758, let-7b, 
etc., are associated with different stages of the viral life cycle and the progression of infection 
[111]. Circulating miRNAs, miR-122, and miR-222 have been shown to be valuable as poten-
tial future diagnostic tool for HCV infection within the Egyptian patients [112]. Upregulated 
miR-10a/15a/17-5p were associated with HCV-related HCC, miR-122 was characterized as 
potential diagnostic tool for HCC within HCV-infected individuals, while overexpression of 
miR-221/222-3p was characteristic exclusively for HCV-related HCC [108]. MicroRNA 122 is 
a liver-specific miRNA, a regulator of HCV tendency to infect hepatic cells. miR-122 is cru-
cial for efficient HCV infection and viral spread and speed up the replication of the virus in 
hepatocytes, and facilitates viral protein synthesis [113]. Besides miR-122, as the mostly studied 
miRNA in HCV-HCC patients that recognizes two different sites at HCV 5’UTR, increased 
levels of miR-448 and miR-196 attenuate HCV replication by binding to the Core and NS5A 
sequences of the HCV genome [114]. Secondly, some miRNAs, such as miR-199a have opposing 
characteristics during the HCV infection. Namely, miR-199 targets sequences of HCV genome 
and blocks the transcription of HCV RNA [115]. Thirdly, during the HCV infection, miR-155 is 
usually up-regulated. Higher levels of the well-known onco-miRNA, miR-155 induce prolifera-
tion of hepatocytes, increasing the chance of HCC formation [116]. For example, changes in the 
expression levels of miRNAs such as miR-134/320c/483-5p were shown to be significantly higher 
within the HCV-infected individuals, compared with healthy controls. In our previous article, 
we described heterogeneity in behavior of microRNA in cancer studies [109, 117]. Another evi-
dence is supporting our observation on the importance to notice how level changes of the par-
ticular miRNA can be important for one event, while having no significance for another similar 
event, related to the same type of the disease or pathological condition, showing high specificity 
of some miRNA molecules. Namely, miR-20a/92a levels investigated in the sera of the patients 
having HCV-related liver disease were associated with the disease severity, and the higher 
grade of liver fibrosis, while levels of the same miRNAs have not shown any association with 
grade of liver fibrosis and other pathological characteristics examined within the patients with 
non-HCV-related liver diseases. Another example of involvement of miRNAs in various seg-
ments of HCV-HCC pathology, HCV proteins change levels of miR-193a that results in reduc-
tion of sensitivity to chemotherapy of HCC patients [118]. Furthermore, in our article related to 
the heterogeneity of miRNAs. According to several researches, it has been shown that miR-122 
may be anti-tumorigenic properties in mice knockdown studies [119].
2.2.2. MicroRNA as future therapeutics for HCV and HCC
Considering the fact that several miRNAs can modulate expression of up to a dozens or even 
hundreds of target genes, it is not surprising that miRNA-based therapy is still challenging. 
Nevertheless, this multi-targeting ability also represents an advantage for future miRNA-
based therapeutics. There are two major approaches for future miRNA-related therapeutics 
miRNA inhibition (Lock nucleic acid (LNA) anti miRNAs, antago miRNAs, miRNA zippers, 
small molecules inhibitors of miRNAs, and miRNA sponges) and miRNA substitution strate-
gies (miRNA mimics and miRNA vectors), with the purpose to either silence miRNA activity 
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or to replace absent miRNA molecules [109, 110]. Several studies proposing that miRNA pan-
els could be used in near future as biomarkers for screening of the HCV-related liver diseases. 
The changes in their expression levels were associated with staging of liver disease progres-
sion and anti-HCV therapeutics [108]. Probably, manipulation with several miRNAs at the 
same time might be crucial in treatment of HCV-HCC. For example, inhibition of upregu-
lated miRNAs involved in viral replication, such as miR-122, simultaneously with miRNAs, 
in combination with inhibition of miRNA such as miR-155 which promotes cancerogenesis, 
or mimicking miRNA whose under expression helps HCV replication, and mimicking down-
regulated miRNA with tumor suppressive function in HCC.
3. Nomenclature
The Family: Flaviviridae, Genus: Hepacivirus, species: Hepacivirus C.
(Guidelines of the International Committee on Virus Taxonomy (ICTV) https://talk.ictvonline.
org/)
4. Conclusions
Chronic HCV infection ultimately leading to HCC will remain a global health problem in 
the coming decades. Despite increasing knowledge regarding mechanisms of HCV-induced 
HCC, prevention of HCV-induced HCC is not yet fully established. So, it is important to 
define both viral- and host genetic and epigenetic patterns on the onset of infection and in 
early and advanced stages of inflammation and fibrosis in order to predict response to the 
antiviral therapy, and thus avoid potential complications of persistent HCV infection. Further, 
for screening a population and making a correct diagnosis about the presence of infection, it 
is necessary to use standardized commercial tests with universal values and analyze homog-
enous group of patients. Despite new DAAs therapy, this virus remains unbeatable. When 
the heterogeneity of the HCV virus, the host genetic and epigenetic variability, and the differ-
ences in the therapy outcomes are taken into account, the only right way to fight this disease 
is personalized therapy.
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